Arkolith/Insider Trading/ARDS/Form 4

Patzer Eric

Executive Chairman, DirectorAridis Pharmaceuticals, Inc. (ARDS) · full profile →Form 4 · filed Jun 15, 2023
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
3
1 non-derivative · 2 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jun 5, 2023Option exercise(M)12K——714K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Jun 5, 2023Option exercise(M)12K——12K
May 4, 2023Grant(A)30K—$0147K

Transaction Codes

M
Option exercise / conversion
A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-23-021487) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML